anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). For participants in Cohort C where induction chemotherapy is used, additional pre-treatment 18F-FMISO PET and post induction pre radiation FMISO PET Scans will be obtained. These patients will start with induction chemotherapy of carboplatin, paclitaxel with or without cetuximab for 6 weeks and follow the same precision chemoradiation algorithm as Cohort A. A window of +/- 2 days is acceptable during the induction phase Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel). For patients who cannot tolerate paclitaxel, Abraxane and the dose will be at 100mg/m\^2.
Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.
The invention belongs to the technical fields of biological medicine and molecular biology, and particularly relates to ROS (reactive oxygen species) response poly-precursor liquid medicine gel and a preparation method and application thereof. In particular, the present invention provides a ROS-sensitive prodrug capable of forming a polyprodrug with polyvinyl alcohol. The prodrug remains inactive until activated by active oxygen, which inhibits Na  +  The channel produces local anesthesia and analgesia. In addition, the present invention creates an in situ formed ROS-responsive pro-polyhydrogel with ROS cleavable linkers. The hydrogel allows for the on-demand release of tetracaine and extends its narcotic analgesic time. In summary, the prodrug systems and subsequently formed hydrogels provided by the present invention have great potential in the delivery of local anesthetic drugs and thus have great value for potential practical applications.
Participants randomized to view TikTok influencers' posts with food will view 4 ads associated with their condition and 2 filler ads, all of which are presented in counterbalanced order. They will report their reaction to the ads using the icons available on the TikTok platform (i.e. like, comment, or share). After viewing all of the TikTok ads, youth participants will complete the virtual snack selection task where they will see a virtual vending machine. All items will cost $2. Participants will be asked to select one snack and one beverage from the vending machine. After the snack selection task, participants will review the TikTok ads again and complete survey questions.
BACKGROUND: Ketamine has been considered as an adjunct for children who do not reach their predefined target sedation depth. However, there is limited evidence regarding the use of ketamine as a prolonged infusion (i.e., >24 hours) in the pediatric intensive care unit (PICU).
OBJECTIVE: We sought to evaluate the safety and effectiveness of continuous ketamine infusion for >24 hours in mechanically ventilated children.
METHODS: We conducted a prospective cohort study in a tertiary PICU from January 2020 to December 2022. The primary outcome was the incidence of adverse events (AEs) after ketamine initiation. The secondary outcome included assessing the median proportion of time the patient spent on the Richmond Agitation-Sedation Scale (RASS) goal after ketamine infusion. Patients were also divided into two groups based on the sedative regimen, ketamine-based or non-ketamine-based, to assess the incidence of delirium.
RESULTS: A total of 269 patients were enrolled: 73 in the ketamine group and 196 in the non-ketamine group. The median infusion rate of ketamine was 1.4 mg/kg/h. Delirium occurred in 16 (22%) patients with ketamine and 15 (7.6%) patients without ketamine (p = 0.006). After adjusting for covariates, logistic regression showed that delirium was associated with comorbidities (odds ratio [OR] 4.2), neurodevelopmental delay (OR 0.23), fentanyl use (OR 7.35), and ketamine use (OR 4.17). Thirty-one (42%) of the patients experienced at least one AE following ketamine infusion. Other AEs likely related to ketamine were hypertension (n = 4), hypersecretion (n = 14), tachycardia (n = 6), and nystagmus (n = 2). There were no significant changes in hemodynamic variables 24 h after the initiation of ketamine. Regarding the secondary outcomes, patients were at their goal RASS level for a median of 76% (range 68-80.5%) of the time in the 24 hours before ketamine initiation, compared with 84% (range 74.5-90%) of the time during the 24 h after ketamine initiation (p < 0.001). The infusion rate of ketamine did not significantly affect concomitant analgesic and sedative infusions. The ketamine group experienced a longer duration of mechanical ventilation and a longer length of stay in the PICU and hospital than the non-ketamine group.
CONCLUSION: The use of ketamine infusion in PICU patients may be associated with an increased rate of adverse events, especially delirium. High-quality studies are needed before ketamine can be broadly recommended or adopted earlier in the sedation protocol.
Significance: Cancer is a complex and heterotypic structure with a spatial organization that contributes to challenges in therapeutics. Enzymes associated with producing the gasotransmitter hydrogen sulfide (H2S) are differentially expressed in tumors. Indeed, critical and paradoxical roles have been attributed to H2S in cancer-promoting characteristics by targeting both cancer cells and their milieu. This review focuses on the evidence and knowledge gaps of H2S on the tumor redox microenvironment and the pharmacological effects of H2S donors on cancer biology. Recent Advances: Endogenous and pharmacological concentrations of H2S evoke different effects on the same cell type: physiological H2S concentrations have been associated with tumor development and progression. In contrast, pharmacological concentrations have been associated with anticancer effects. Critical Issues: The exact threshold between the promotion and inhibition of tumorigenesis by H2S is largely unknown. The main issues covered in this review include H2S-modulated signaling pathways that are critical for cancer cells, the potential effects of H2S on cellular components of the tumor microenvironment, temporal modulation of H2S in promoting or inhibiting tumor progression (similar to observed for inflammation), and pharmacological agents that modulate H2S and which could play a role in antineoplastic therapy. Future Directions: Given the complexity and heterogeneity of tumor composition, mechanistic studies on context-dependent pharmacological effects of H2S donors for cancer therapy are necessary. These studies must determine the critical signaling pathways and the cellular components involved to allow advances in the rational use of H2S donors as antineoplastic agents. Antioxid. Redox Signal. 40, 250-271.
This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
OBJECTIVES: Lymphatic channels (LC) are not as prominent as blood vessels, so they tend to get damaged during surgical procedures. It can present with chyle leak in the postoperative period. We aimed to study the occurrence of chyle leak in patients undergoing nephrectomy and its management.
METHODS: During the period of January 2021 and January 2023, 158 adult patients underwent nephrectomy for various reasons like non-functioning kidney, donor nephrectomy, and malignancy. We retrospectively analyzed data of patients who had chyle leak after nephrectomies.
RESULTS: Eight patients out of the 158 patients (5.06%) undergoing nephrectomy developed chyle leak. One out of these eight patients underwent nephrectomy by open approach while seven underwent laparoscopic approach. All eight patients who had chyle leak undergone left sided nephrectomy. Six patients of chyle leak could be managed with dietary modification while two patients needed octreotide therapy for treatment. Higher Body Mass Index (BMI; p-value = 0.012), left sides nephrectomy (p-value = 0.013), h/o pyelonephritis (p-value = 0.005) were associated with higher incidence of chyle leak on univariate analysis. While on multivariate analysis no factor was found to be independently associated with chyle leak. Hospital stay was significantly prolonged in patients with chyle leak (p-value = 0.007).
CONCLUSION: Chyle leak is not a very rare complication after nephrectomy. Patients with higher BMI, who undergo left sided nephrectomies and patients who had history of pyelonephritis or infectious complications had higher incidence of chyle leak. Most cases can be managed with conservative management (CM). Chyle leak is associated with a prolonged hospital stay.
Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
An ocular drug delivery system comprising a nanofiber matrix, wherein said nanofiber matrix comprises drug-containing nanoparticles. Preferably, the nanoparticles are impregnated in the nanofiber matrix. The nanoparticles may comprise a biodegradable, hydrophobic polymer, most preferably poly(lactic-co-glycolic acid) (PLGA); and/or a biodegradable, amphiphilic polymer selected from various polyethylene glycol block co-polymers. Preferably, the drug is selected from an anti-microbial, anti-inflammatory, anti-glaucoma, analgesic, an anaesthetic or combinations thereof, an exemplified drug is azithromycin. The nanofiber may comprise a mucoadhesive polymer, preferably polyvinylpyrrolidone. The drug delivery system may be an ocular insert, preferably a patch. Preferably, the system of the invention provides controlled-release of drug over a period of at least 3 days. A method of making said ocular drug delivery system is also disclosed; comprising preparing nanofibers impregnated with drug-containing nanoparticles, preferably by electrospinning; then forming the resulting nanofibers into said ocular drug delivery system. Also claimed are an ocular drug delivery system for use in the treatment of ocular diseases and a method of treating an ocular disease in a patient, comprising placing said ocular drug delivery system into the eye of said patient and maintaining said system in said eye for a therapeutically effective period of time.
PROBLEM TO BE SOLVED: To obtain a sheetlike plaster capable of readily evaporating water or the like coated at the time of application and shortening the drying time without a sticky feeling at a low cost by arranging an application layer composed of a wet tacky composition and a holding layer in a specified structure. SOLUTION: This sheetlike plaster comprises an application layer 20 composed of a wet tacky composition and a holding layer 10 for holding the application layer 20 and is obtained by arranging the application layer 20 so as to expose a part of the application layer 20 to the side of a nonapplication surface of the holding layer 10. The exposed area of the application layer 20 is preferably 10-60% based on the plane area of the sheetlike plaster. The holding layer 10 is preferably a netlike woven or nonwoven fabric. (A) Polyvinylpyrrolidone or/and a polyvinylpyrrolidone-vinyl acetate copolymer, (B) a liquid plasticizer compatible with the ingredient A and (C) a filter are preferably contained in the wet tacky composition.  Since the plaster provides the holding layer 10 in a state thereof firmly entering the application layer, the mechanical strength is increased and peeling residues are hardly caused.
PURPOSE:A sustained release suppository gradually releasing a drug to digestive tubes and keeping medicinal effects for a long period, obtained by blending a high-melting suppository base with hydrogenated lecithin. CONSTITUTION:100pts.wt. high-melting suppository base having 40-45 deg.C melting point is blended with >=5pts.wt. hydrogenated lecithin. Prolongation can be regulated by properly selecting the amount of the hydrogenated lecithin blended, can suppress rapid rise in drug concentration in blood after suppository administration and prevent side effects caused by drug. An anti-inflammatory analgesic is especially preferable as the suppository used.
Provided are an ophthalmologic apparatus and a storage medium capable of appropriately evaluating the in-focus state of an anterior segment image. The ophthalmologic apparatus includes an index light projection unit and an anterior eye imaging unit. The index projection unit projects an index to the eye to be inspected. The anterior segment photographing section photographs an anterior segment image of the eye to be inspected. The control unit of the ophthalmologic apparatus acquires the anterior segment image captured by the anterior segment capturing unit (S2). The control unit acquires the intensity of the luminance gradient at each pixel of the anterior segment image captured by the anterior segment capturing unit (S4). The control unit evaluates the focus state at the time of capturing the anterior segment image based on the obtained luminance gradient intensity having a value of a specific rank (S6).
PURPOSE:To obtain an improved lyophilized pharmaceutical preparation of B- type hepatitis vaccine having no reduction in titer, stability, and solubility of rapid disssolution, obtained by adding aluminum gel and a stabilizer to a surface antigen of deactivated purified B-type hepatitis virus, lyophilizing it. CONSTITUTION:A surface antigen of deactivated purified B-type hepatitis virus (HBsAg for short) is blended with a aluminum gel (aluminum hydroxide gel, aluminum phosphate gel) and a stabilzer, and lyophilized to give a lyophilized pharmaceutical preparation of B-type hapatitis vaccine. The stabilizer consists of one of an amino acid or its salt (e.g., glycine, alanine, lysine, etc.) and a saccharide (e.g., glucose, xylose, etc.), preferably both, and, more preferably, a colloidal agent (e.g., gelatine, dextran, etc.). It has better storage stability than liquid HBsAg, no reduction in titer, and good solubility in use.
Under the original protocol, patients were to have their treatment dose titrated upwards from a starting dose of 10mg b.i.d. to 15mg b.i.d. and then to a stable (maintenance) dose of 20mg b.i.d. The protocol was subsequently revised to lower the maximum maintenance dose. In the most current protocol, all patients were down-titrated to 10mg b.i.d. and maintained at this dose for the greater part of the duration of the study.

Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. As a result, patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with MS. This study will evaluate the effects and possible risks of taking Fampridine-SR in MS patients over a long period of time.
An oxygen delivery system is disclosed. The basis of the oxygen deliver system is a carbide-derived carbon (CDC). The CDC can be tuned to carry O 2  directly (CDC OC), or hemoglobin can be adsorbed to provide a hemoglobin-based oxygen carrier (CDC HBOC). The delivery system allows the use of a variety of hemoglobins which differ in their oxygen dissociation profiles, including variant and mutant hemoglobins from other species. The delivery system is biocompatible and stable, and is able to irreversibly bind and hold large amounts of functional hemoglobin variants. The CDC HBOC and CDC OC provide a safe and effective blood substitute for combat casualty care, as well as being useful for oxygen delivery in other contexts.
Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in Chinese participants, who reside in China, have histologically or cytologically-confirmed advanced/metastatic solid tumor, and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
A system for responding to natural-language inquiries is described. The system accesses a textual natural language inquiry originated by a user. For each of one or more inquiry attributes, the system extracts from the textual natural language query a value for the inquiry attribute. The system uses the extracted inquiry attribute values to construct one or more HIPAA requests seeking information relevant to the inquiry. The system submits the constructed requests to a payer computer system. In response to submission of the constructed requests, the system receives from a payer computer system one or more HIPAA responses. Using information contained by at least one of the received HIPAA responses, the system generates a textual natural language response.
There will be no screening period for this study. Eligible subjects can start their treatment with osilodrostat as soon as they are enrolled in the study. The first study visit will be scheduled at the time of the last study visit for the parent study. Subjects must return to the study center at least on a quarterly basis (every 12 weeks ± 2 weeks) for safety and clinical benefit assessments, and resupply of study medication. Drug dispensing and administration information and adverse events will be collected. The subject may return to the clinic at any given time as per standard of care or treating physician recommendation; however, only the quarterly study visits will be recorded in the Case Report Form (CRF). Study medication dispensed will be recorded in the CRF dose administration page.

All adverse events and serious adverse events, including pregnancy, will be collected throughout the study. Subjects will continue to be treated in this roll-over study until they are no longer benefiting from their osilodrostat treatment as judged by the Investigator or until osilodrostat is commercially available or until one of other discontinuation criteria is met.
Two clinical trials (Study 1 and Study 2) in adults compared CLINOLIPID to soybean oil-based intravenous lipid emulsion. Although Study 1 and Study 2 were not adequately designed to demonstrate noninferiority of CLINOLIPID to the soybean oil comparator, they support CLINOLIPID as a source of calories and essential fatty acids in adults. The lipid dosage was variable in Studies 1 and 2 and adjusted to the patient’s nutritional requirements.

Study 1 was a randomized, open-label, multicenter study. Forty-eight patients, aged 17 to 75 years, requiring total parenteral nutrition (TPN) for ≥15 days (mean 22 days) were enrolled and randomized to either CLINOLIPID or a 100% soybean oil-based intravenous lipid emulsion. Nutritional efficacy was assessed by anthropometric indices (body weight, arm circumference, skin-fold thickness), biomarkers of protein metabolism (total protein, albumin) and lipid metabolism. Anthropometric criteria (body weight, arm circumference, and skin fold thickness) were comparable for both groups. Mean total serum protein and albumin increased similarly in both groups.

Study 2 was a randomized, open label multicenter study that enrolled 22 patients aged 32-81 years who required long-term parenteral nutrition. Twelve patients received CLINOLIPID for a mean of 202 days (range 24 to 408 days) and 10 patients received the comparator lipid for a mean of 145 days (range 29-394 days). The two groups had similar outcomes for weight, weight loss, mid-arm circumference and triceps skinfold thickness.
The invention uses the technology of the common USB (flash) drive to hold a person's medical history and can be carried on a key chain or in your pocket or purse. The medical history is entered by the owner of the USB drive and is protected by a user ID and password. The invention provides for the digital storage and retrieval of user's medical records that includes drug prescriptions, medical history, doctors, religion preference, living will, medical power of attorney and personal identification. Information can be retrieved and read by any window's base computer that has an available USB port. This invention will self boot and give you access to a medical emergency screen that shows vital information in matter of seconds without a users password all other information stays private. Data is encrypted to ensure security on the drive and a copy can be placed on the local hard drive and/or in a secure database via the internet, that can be accessed anywhere, 24/7 using your ID and password.
Acute lung injury is one of the most serious complications of sepsis, which is a common critical illness in clinic. This study aims to investigate the role of caspase-3/ gasdermin-E (GSDME)-mediated pyroptosis in sepsis-induced lung injury in mice model. Cecal ligation (CLP) operation was used to establish mice sepsis-induced lung injury model. Lung coefficient, hematoxylin and eosin staining and transmission electron microscopy were used to observe the lung injury degree. In addition, caspase-3-specific inhibitor Z-DEVD-FMK and GSDME-derived inhibitor AC-DMLD-CMK were used in CLP model, caspase-3 activity, GSDME immunofluorescence, serum lactate dehydrogenase (LDH) and interleukin-6 (IL-6) levels, TUNEL staining, and the expression levels of GSDME related proteins were detected. The mice in CLP group showed the increased expressions of cleaved-caspase-3 and GSDME-N terminal, destruction of lung structure, and the increases of LDH, IL-6, IL-18 and IL-1β levels, which were improved in mice treated with Z-DEVD-FMK or AC-DMLD-CMK. In conclusion, caspase-3/GSDME mediated pyroptosis is involved in the occurrence of sepsis-induced lung injury in mice model, inhibiting caspase-3 or GSDME can both alleviate lung injury.